Autolus Therapeutics plc, a biopharmaceutical company listed on Nasdaq, announced on July 15, 2025, that its Board of Directors' compensation committee has granted stock option awards to 60 employees under the 2025 Inducement Plan. These options allow for the purchase of a total of 360,550 shares of common stock at an exercise price of $2.47 per share, matching the closing price on July 9, 2025. Each option comes with a ten-year term and vests over four years, with 25% vesting after the first year and the remainder vesting in equal monthly installments over the following three years, contingent on ongoing employment with Autolus.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。